Stocks-Prognosis.com
Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site



JJ to buy psychiatric drug developer Intra-Cellular for 14.6B

January 15, 2025
In a major move to bolster its presence in the mental health sector, pharmaceutical giant JNJ Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for a staggering $14.6 billion. This acquisition marks a significant expansion for JNJ in the field of psychiatric drug development.

Intra-Cellular Therapies is a biopharmaceutical company focused on the development of treatments for central nervous system disorders, including schizophrenia and bipolar disorder. The company's lead drug candidate, lumateperone, has shown promising results in clinical trials and has the potential to revolutionize the treatment of mental health conditions.

The decision to acquire Intra-Cellular Therapies aligns with JNJ's strategy to diversify its product portfolio and tap into the growing demand for innovative mental health treatments. With a global prevalence of mental health disorders on the rise, there is a pressing need for more effective and accessible therapies.

This acquisition not only strengthens JNJ's position as a leader in the pharmaceutical industry but also reflects its commitment to addressing unmet medical needs. By investing in the development of novel psychiatric drugs, JNJ aims to improve the lives of millions of individuals suffering from mental health disorders.

Analysts predict that this strategic move by JNJ will have a positive impact on its financial performance in the long term. Investors are advised to consult the experts at Stocks Prognosis for a professional forecast of the stock movement following this acquisition.

In conclusion, JNJ's acquisition of Intra-Cellular Therapies for $14.6 billion underscores its dedication to advancing mental health treatments and signals a major breakthrough in the field of psychiatric drug development. With its continued commitment to innovation and meeting unmet medical needs, JNJ is poised to make a significant impact on the lives of patients worldwide.
If you want to leave a comment, then you need Login or Register





Other data for JNJ

Related data

JNJJuly 14, 2025Johnson & Johnson Innovates with New Product Launches  ~1 min.

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA....

JNJMay 25, 2025Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology  ~1 min.

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....

JNJMarch 21, 2025Johnson & Johnson Neurovascular leader heads for the exit  ~1 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJMarch 20, 2025Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals  ~2 min.

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....

JNJMarch 19, 2025FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy  ~1 min.

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJMarch 18, 2025Johnson & Johnson MedTech Introduces New EP Neurovascular Leader  ~1 min.

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group....

JNJMarch 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments  ~1 min.

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....

JNJFebruary 28, 2025Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations  ~1 min.

Johnson & Johnson (JNJ) has shown an impressive 8.9% increase in its stock price since the release of its last earnings report....

JNJFebruary 26, 2025The surgical devices I design for JJ speed healing and save lives  ~1 min.

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives....

JNJFebruary 18, 2025Johnson & Johnson reportedly wants to sell Cerenovus for 1B  ~1 min.

According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....

JNJJanuary 14, 2025Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout  ~1 min.

Johnson & Johnson, one of the world's largest pharmaceutical companies, has announced its acquisition of psychiatric drug developer Intra-Cellular. The deal, valued at $14....

ABBVNovember 14, 2024AbbVie Faces Setback as Schizophrenia Drug Trials Fall Short  ~2 min.

Pharmaceutical giant AbbVie Inc. (ABBV) experienced a significant drop in stock prices today, following disappointing results from their latest schizophrenia drug trials....

REGNJanuary 29, 2025Regeneron Pharmaceuticals Inc. REGN: A Leader in Biopharmaceutical Innovation  ~2 min.

Regeneron Pharmaceuticals Inc. (REGN) is a biopharmaceutical company known for its pioneering work in developing innovative therapies....

VRTXFebruary 13, 2025Vertex Pharmaceuticals Announces Impressive Q4 2024 Earnings and FDA Approval of Key Drugs  ~2 min.

Vertex Pharmaceuticals Incorporated (VRTX), a leading biotechnology company, has reported its strong financial results for the fourth quarter and full year of 2024....

GSKJanuary 15, 2025GSK Acquires IDRx for 1B Gaining Breakthrough GIST Cancer Drug  ~2 min.

GSK PLC, a leading pharmaceutical company, has recently announced its acquisition of IDRx, a US-based biotech business, for a staggering amount of 1 billion dollars....